COMPANY

ConSynance Therapeutics

ConSynance Therapeutics is a clinical-stage biopharmaceutical company. From company website Source · Oct 13, 2026

Keywords: biopharmaceutical therapeutics Prader-Willi Syndrome CSTI-500

Profile checked Oct 10, 2026

Timeline

2026-05 Trial start Phase 2: A Study of CSTI-500 in Patients With Prader-Willi Syndrome source ↗
Nov 14, 2022 Trial start Phase 1: A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome source ↗

2027-06 (ESTIMATED) · Phase 2 · A Study of CSTI-500 in Patients With Prader-Willi Syndrome · NCT07348601

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07348601	A Study of CSTI-500 in Patients With Prader-Willi Syndrome	Phase 2	Recruiting	2026-05	2027-06 (estimated)
NCT05504395	A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome	Phase 1	Completed	Nov 14, 2022	Feb 21, 2023 (actual)